PRESS RELEASE
24 March 2026

Mintz Advises On SAB Biotherapeutics’ $85 Million Public Offering

M
Mintz

Contributor

Mintz is a litigation powerhouse and business accelerator serving leaders in life sciences, private equity, sustainable energy, and technology. The world’s most innovative companies trust Mintz to provide expert advice, protect and monetize their IP, negotiate deals, source financing, and solve complex legal challenges. The firm has over 600 attorneys across offices in Boston, Los Angeles, Miami, New York, Washington, DC, San Francisco, San Diego, and Toronto.
Mintz advised the underwriters in connection with SAB Biotherapeutics’ $85 million public offering.
United States

Mintz advised the underwriters in connection with SAB Biotherapeutics' $85 million public offering.

Jefferies, UBS Investment Bank, Citigroup, and Barclays acted as joint book-running managers for the offering. Chardan acted as lead manager.

The Mintz capital markets team included William Hicks, John Rudy, Alok Choksi, Hannah Karraker, Gretchen Goyette, Patricia Garza Gonzalez, and Kate McLeod. Ari Feder advised on tax matters, Jenny Chen advised on intellectual property matters, and Joanne Hawana advised on regulatory matters. Members of the Mintz team are based in the Boston, New York, San Diego, and Washington, DC offices.

Contributor

Mintz is a litigation powerhouse and business accelerator serving leaders in life sciences, private equity, sustainable energy, and technology. The world’s most innovative companies trust Mintz to provide expert advice, protect and monetize their IP, negotiate deals, source financing, and solve complex legal challenges. The firm has over 600 attorneys across offices in Boston, Los Angeles, Miami, New York, Washington, DC, San Francisco, San Diego, and Toronto.

Mondaq uses cookies on this website. By using our website you agree to our use of cookies as set out in our Privacy Policy.

Learn More